Pages that link to "Q33820374"

The following pages link to Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models (Q33820374):

Displaying 30 items.

• Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade (Q27853295) (← links)
• Dual roles of extracellular signal-regulated kinase (ERK) in quinoline compound BPIQ-induced apoptosis and anti-migration of human non-small cell lung cancer cells (Q29248583) (← links)
• Overexpression of P21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion (Q35646176) (← links)
• Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma (Q35837200) (← links)
• Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer (Q35839063) (← links)
• Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer (Q36200159) (← links)
• Inactivation of PI3-K/Akt and reduction of SP1 and p65 expression increase the effect of solamargine on suppressing EP4 expression in human lung cancer cells (Q36393799) (← links)
• Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities. (Q36398758) (← links)
• N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells (Q36651651) (← links)
• Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma (Q36725307) (← links)
• Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer (Q36804624) (← links)
• PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition (Q36899519) (← links)
• Over-expression of DNA-PKcs in renal cell carcinoma regulates mTORC2 activation, HIF-2α expression and cell proliferation (Q37093230) (← links)
• Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer (Q37245874) (← links)
• Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. (Q37588461) (← links)
• Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC (Q37645002) (← links)
• In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC (Q37694812) (← links)
• Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities (Q38733117) (← links)
• Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations (Q38740315) (← links)
• ERK Signaling Pathway Is Involved in HPV-16 E6 but not E7 Oncoprotein-Induced HIF-1α Protein Accumulation in NSCLC Cells (Q38789833) (← links)
• Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization (Q38825141) (← links)
• The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines (Q38860372) (← links)
• Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells (Q42316990) (← links)
• Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS. (Q42330188) (← links)
• PI3K: A Crucial Piece in the RAS Signaling Puzzle (Q47894525) (← links)
• Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. (Q49180082) (← links)
• Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution. (Q54388141) (← links)
• Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway (Q60303261) (← links)
• Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs (Q90293775) (← links)
• Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization (Q92027154) (← links)